Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 29, 2024



Dynavax Technologies Corporation

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)






2100 Powell Street, Suite 720


Emeryville, California



(Address of Principal Executive Offices)


(Zip Code)


Registrant’s Telephone Number, Including Area Code: 510 848-5100



(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class




Name of each exchange on which registered

Common Stock, $0.001 par value




Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 29, 2024, Dynavax Technologies Corporation (the “Company”) appointed Ryan Spencer to serve in a temporary capacity as Interim Chief Financial Officer (principal financial officer) of the Company while Kelly MacDonald is on maternity leave, commencing April 1, 2024. Ms. MacDonald is expected to return in early August 2024, at which time Ms. MacDonald will resume her role as Chief Financial Officer (principal financial officer) of the Company. During Ms. MacDonald’s absence, other officers of the Company have assumed certain of Ms. MacDonald’s duties while remaining in their current positions, with the addition of a senior-level consultant with public company Chief Financial Officer experience.

Mr. Spencer currently also serves as the Company’s Chief Executive Officer and as a member of the Board. There will be no change in Mr. Spencer’s compensation as a result of this appointment. Biographical information for Mr. Spencer is available in the Company’s proxy statement filed with the Securities and Exchange Commission on April 13, 2023 in connection with the Company’s 2023 annual meeting of stockholders, such information being incorporated herein by reference.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




Dynavax Technologies Corporation






April 1, 2024


/s/ Ryan Spencer




Ryan Spencer
Chief Executive Officer